PTGX Protagonist Therapeutics, Inc.
USHealthcareAs of 2026-07-08 16:00
Why PTGX matters now
Protagonist Therapeutics, Inc. (PTGX) is a US stock in Healthcare. The latest InvestLog snapshot shows $140.07 with -0.55% on the session and $9.01B in market capitalization; recent performance reads 1-month +14.73% and YTD +29.22%.
The latest financial table shown here is Q1 2026, with revenue of $56.4M, net income of $3.8M, and EPS of $0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1.6%.
The latest indexable market news headline is "New Strong Buy Stocks for July 9th" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Buy with a median target of $119.00; recent insider activity includes Waddill William D. filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
11.21
P/S
98.00
EV/EBITDA
-62.09
DCF Value
$-9.63
FCF Yield
-1.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.5%
Operating Margin
-192.4%
Net Margin
-154.9%
ROE
-17.8%
ROA
-16.4%
ROIC
-21.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $56.4M | $3.8M | $0.05 |
| Q4 2025 | $7.4M | $-44.4M | $-0.69 |
| FY 2025 | $46.0M | $-130.1M | $-2.05 |
| Q3 2025 | $4.7M | $-39.3M | $-0.62 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$117.25
Target (Median)
$119.00
Target Range
$110.00 - $121.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.83
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.